Systemic inflammation and non-alcoholic fatty liver disease

Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease, leading to deterioration in the quality of life, invalidism and mortality, due to the high risk of progression with the development of nonalcoholic steatohepatitis (NASH), cirrhosis and hepatocellular carcinoma. In the development of NAFLD, an important place is given to systemic inflammation, which determines the development of metabolic and clinical manifestations against the background of genetic predisposition initiating the development of NAFLD, and its progression to NASH, fibrosis, cirrhosis and hepatocarcinoma. Laennec is a multicomponent drug based on the hydrolyzed of human placenta, which has a proliferative effect on the hepatocytes, connective tissue cells, other structures of the liver. This paper presents the results of the analysis of molecular mechanisms of action of peptide components of Laennec on pathophysiological mechanisms of development and progression of NAFLD. The efficacy of the drug in patients with NASH in the form of monotherapy for 4 months was shown. Conclusion: it was found that one of the drugs that contribute to the reduction of systemic inflammation in NAFLD is Laennec.

неалкогольная жировая болезнь печени (НАЖБП), неалкогольного стеатогепатита (НАСГ) системное воспаление, инсулинорезистентность, пептиды гидролизата плаценты человека, Лаеннек, nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), systemic inflammation, insulin resistance, human placenta hydrolysate peptides, Laennec